Sunday, October 25, 2020
Home Tags Pivotal

Tag: pivotal

SoniVie Receives IDE Approval for its Pivotal Study for the TIVUS...

International study designed to build on positive 12-month data from TROPHY1 demonstrating improvement in multiple clinical endpoints and no serious procedure-related adverse events TEL AVIV,...

Kyowa Kirin and MEI Pharma Announce First Patient Dosed in Japanese...

This Phase 2, multicenter, open-label, single-arm clinical study is conducted by Kyowa Kirin to evaluate zandelisib as monotherapy for treatment of Japanese patients with...

Arcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical...

Roflumilast cream potential “Best in Class” topical PDE4 inhibitorPlaque psoriasis affects approximately 8.6 million patients in the U.S.Phase 3 trials topline data now anticipated...

miRagen Announces Results of Meeting With FDA Regarding the Design of...

BOULDER, Colo., Aug. 20, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and...

NHS telemedicine ambitions approach a pivotal point –

The UK government has said it is vital to adopt telemedicine across the NHS in response to COVID-19 – but is the health service...

Pivotal rucaparib phase 3 mCRPC data published

The pivotal findings from the phase 3 TRITON2 trial, which led to the FDA approval of rucaparib (Rubraca) in BRCA-positive metastatic castration-resistant prostate cancer...

Pegram Unpacks Pivotal Data in Breast Cancer

Welcome to a very special edition of OncLive® On Air! I’m your host today, Caroline Seymour.OncLive® On Air is a podcast from OncLive, which...

Independent Review Committee Recommends Nordic Nanovector to focus on one dosage...

OSLO, Norway, Aug. 6, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) today announces that, following a planned interim analysis of the PARADIGME Phase 2b...

BRIEF-Exelixis Announces Initiation Of Phase 3 Pivotal Trial For Previously Treated...

June 30 (Reuters) - Exelixis Inc: * EXELIXIS ANNOUNCES INITIATION OF CONTACT-02 PHASE 3 PIVOTAL TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB IN PREVIOUSLY...

Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib...

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc.. (NASDAQ: EXEL) today announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination...
20,764FansLike
2,400FollowersFollow
16,600SubscribersSubscribe

EDITOR PICKS